Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum

29 Jan 2026 08:30 CET

Arctic Bioscience are pleased to announce that we have been invited to present
at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in
the session 'The Perfect Dose: Innovating Drugs and Drug Delivery'.

Our Medical Director, Runhild Gammelsæter, will be presenting our latest
pipeline project, ABS403, with the aim to promote resolution of inflammation and
support neuroprotection in glaucoma. This eye disease does not currently have a
cure and leads to blindness.

The project was initiated based on encouraging clinical signals from a pilot
study in glaucoma (POAG).

As we prepare for the next stages, we are actively seeking partners and
investors to join us in advancing ABS403 into further clinical development.

Read more about the event: https://glaucoma360.org/

Read more about the promising pilot trial by Luo et al:
https://doi.org/10.1007/s10792-025-03693-1

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site